Yesterday, Solid Biosciences issued a press release following receipt of written communication from the USA FDA regarding the clinical hold placed on their IGNITE DMD Phase I/II clinical trial. Please find below links to their press release and the corresponding letter they drafted to the Duchenne community.

Community Letter:

Press Release: